# Elizabeth R. Plimack

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/elizabeth-r-plimack/

## Facts

| Field | Value |
| --- | --- |
| Citations | 49,597 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 80 |
| i10-index | 257 |
| Last Known Institution | Fox Chase Cancer Center |
| OpenAlex ID | https://openalex.org/A5032422193 |
| ORCID iD | https://orcid.org/0000-0002-7618-0744 |
| Works | 775 |

## Researcher papers

- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/prostate-cancer-version-2-2019-nccn-clinical-practice-guidelines-in-oncology/)
- [Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial](https://scholariq.org/papers/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer-long-term/)
- [Prostate Cancer](https://scholariq.org/papers/prostate-cancer-2/)
- [Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/kidney-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Prostate Cancer, Version 1.2016](https://scholariq.org/papers/prostate-cancer-version-1-2016/)
- [Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology](https://scholariq.org/papers/bladder-cancer-version-1-2026-nccn-clinical-practice-guidelines-in-oncology/)
- [Prostate Cancer, Version 2.2014](https://scholariq.org/papers/prostate-cancer-version-2-2014/)
- [NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022](https://scholariq.org/papers/nccn-guidelines-insights-bladder-cancer-version-2-2022/)
- [Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/bladder-cancer-version-5-2017-nccn-clinical-practice-guidelines-in-oncology/)
- [Bladder Cancer, Version 3.2024](https://scholariq.org/papers/bladder-cancer-version-3-2024/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)
- [Multiple and Secondary Primary Cancers](https://scholariq.org/topics/multiple-and-secondary-primary-cancers/)

## Researcher university

- [Fox Chase Cancer Center](https://scholariq.org/institutions/fox-chase-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.